Sedation and Analgesia Using PFK Versus General Anesthesia in Urological Procedures

Sponsor
University of Jordan (Other)
Overall Status
Completed
CT.gov ID
NCT04285528
Collaborator
(none)
200
1
2
9.5
21

Study Details

Study Description

Brief Summary

Anesthesia in urological surgeries might constitute a great challenge to anesthesiologists. Especially that a great proportion of these patients are elderly with a lot of comorbidities. This put these patients at the risk of developing medical adverse events after being anesthetized by general anesthesia. The aim of this study is to compare between intravenous sedation with analgesia versus general anesthesia in patients undergoing urological surgical procedures.

Condition or Disease Intervention/Treatment Phase
  • Drug: General anesthetia Fentanyl and Propofol
  • Combination Product: PFK
N/A

Detailed Description

Anesthesia in urological surgeries might constitute a great challenge to anesthesiologists. Especially that a great proportion of these patients are elderly with a lot of comorbidities. This put these patients at the risk of developing medical adverse events after being anesthetized by general anesthesia. The aim of this study is to compare between intravenous sedation with analgesia versus general anesthesia in patients undergoing urological surgical procedures.

The first group which underwent general anesthesia, was anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Laryngeal mask airway was then inserted.

The second group underwent intravenous sedation and analgesia by using a mixture of Fentanyl, Propofol and Ketamine (PFK mixture). The mixture consists of 100 mcg Fentanyl, 100 mg Propofol, 100 mg of Ketamine. In addition, 40 mg of Lidocaine were added, this aimed to reduce the pain on injection caused by Propofol. Moreover, 4 ml of water of injection were added to the mixture. This resulted in a mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine. By this, each ml of the mixture contained 10 mg (ketamine and propofol) + 5 mcg fentanyl. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on support of 3 L/min O2.

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Intravenous Sedation and Analgesia Using Propofol, Fentanyl and Ketamine (PFK) Versus General Anesthesia in Minor Urological Procedures.
Actual Study Start Date :
Apr 17, 2019
Actual Primary Completion Date :
Dec 1, 2019
Actual Study Completion Date :
Feb 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: General Anesthesia

The first group which will undergo general anesthesia, will be anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Laryngeal mask airway will be inserted afterwards.

Drug: General anesthetia Fentanyl and Propofol
Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
Other Names:
  • GA
  • Experimental: PFK group

    The second group will undergo intravenous sedation and analgesia by using a mixture of Fentanyl, Propofol and Ketamine (PFK mixture). The mixture consists of 100 mcg Fentanyl, 100 mg Propofol, 100 mg of Ketamine. In addition, 40 mg of Lidocaine will be added, this aims to reduce the pain on injection caused by Propofol. Moreover, 4 ml of water for injection will be added to the mixture.

    Combination Product: PFK
    A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
    Other Names:
  • propofol-ketamine-fentanyl (PFK) mixture
  • the mixture of propofol, ketamine, fentanyl, with lidocaine
  • Outcome Measures

    Primary Outcome Measures

    1. Blood pressure stability [45 minutes]

      the investigators recorded the changes in blood pressure after induction of anesthesia

    Secondary Outcome Measures

    1. Hypoxia [45 minutes]

      the investigators recorded any episodes of transient reduction of oxygen saturation.

    2. nausea and vomiting [2 hours]

      The investigators recorded the occurrence of nausea and vomiting till the discharge of the patients from post anesthesia care unit (PACU).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • patients above the age of 30 years

    • patients who were admitted for minor urological surgeries under the care of urology team. Minor urological procedures, included cystoscopy, trans-urethral resection of tumor (TURT), uretroscopy, double J insertion, and double J removal.

    Exclusion Criteria:
    • patient refusal.

    • urgent and emergency cases, which were not elective procedures.

    • Surgeries that were expected to take a long duration (more than 1.5 hour).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Jordan University Hospital Amman Jordan 13046

    Sponsors and Collaborators

    • University of Jordan

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Abdelkarim Saleh AlOweidi, Principal investigator, University of Jordan
    ClinicalTrials.gov Identifier:
    NCT04285528
    Other Study ID Numbers:
    • 67/2019/1166
    First Posted:
    Feb 26, 2020
    Last Update Posted:
    Mar 3, 2020
    Last Verified:
    Feb 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Abdelkarim Saleh AlOweidi, Principal investigator, University of Jordan
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 3, 2020